Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Long-term Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in MDD
2023-508163-74-00Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 22
01
Overview
Phase 3, open-label trial of aticaprant in major depressive disorder (MDD) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse events including adverse events of special interest (AESI), Change from baseline in vital signs and 6 more. Started Oct 2024; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2023-508163-74-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508163-74-00.